Charles Schwab Investment Management Inc Aligos Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 31,383 shares of ALGS stock, worth $10,984. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,383
Previous 31,383
-0.0%
Holding current value
$10,984
Previous $20,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ALGS
# of Institutions
53Shares Held
46.2MCall Options Held
6.11MPut Options Held
200-
Armistice Capital, LLC New York, NY6.89MShares$2.41 Million0.09% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$2.24 Million0.18% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$2.14 Million0.2% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$1.24 Million0.46% of portfolio
-
Altitude Crest Partners Inc. Stamford, CT2.84MShares$995,6381.19% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $13.9M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...